Redona Therapeutics
Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.
Founded
2016Redona Therapeutics: Advancing small molecule therapies for cancer via ncRNA modulation.
Redona Therapeutics, founded with a mission to revolutionize cancer treatment, focuses on the modulation of functional non-coding RNA (ncRNA) to combat cancer and other serious diseases. By targeting ncRNA modulating proteins (RMPs), the company develops small molecule therapies aimed at altering the expression levels of oncogenes and other critical proteins involved in disease progression. Their innovative approach seeks to address unmet medical needs in oncology and potentially other therapeutic areas.
Notable figures associated with Redona Therapeutics include leading scientists and industry experts in RNA biology and drug development. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and development. Key achievements include advancing their pipeline of novel therapeutics and securing patents for their unique ncRNA modulation technologies. Redona Therapeutics is making significant strides in the biotech industry, with a promising impact on future cancer treatments and beyond.
Companies similar to Redona Therapeutics include Nextrna Therapeutics, PIC Therapeutics, Nano RED and Remix Therapeutics.
Redona Therapeutics was founded in 2016.
Redona Therapeutics' headquarters is located in Watertown, MA, US.
Redona Therapeutics' most recent funding round was for $6M (USD) in July 2023.
As of Jul 31, 2023, Redona Therapeutics has disclosed funding of $66.8M (USD). Undisclosed round amounts are excluded.
Redona Therapeutics has 24 employees as of Feb 5, 2024.
remixtx.com
